Cooperative Tandem Catalysis by an Organometallic Complex and a Metalloenzyme

Although chemical and enzymatic catalysts have been combined, reactions in which an organometallic catalyst and a metalloenzyme work cooperatively to create products, which cannot be generated with either catalyst alone or in comparable yields by sequential reactions of the two catalysts, have not been reported. Such reactions are challenging to achieve, in part because the milieu in which these catalysts operate are typically different. Herein, two classes of catalysts are demonstrated to react cooperatively in the same system. Combination of a metathesis catalyst and a P450 enzyme lead to a dynamic equilibration of alkenes and a selective epoxidation of the cross‐metathesis products. These results show the potential of combining the two classes of catalysts for synthetic transformations.     

Formation of High‐Valent Iron–Oxo Species in Superoxide Reductase: Characterization by Resonance Raman Spectroscopy

Superoxide reductase (SOR), a non‐heme mononuclear iron protein that is involved in superoxide detoxification in microorganisms, can be used as an unprecedented model to study the mechanisms of O₂ activation and of the formation of high‐valent iron–oxo species in metalloenzymes. By using resonance Raman spectroscopy, it was shown that the mutation of two residues in the second coordination sphere of the SOR iron active site, K₄₈ and I₁₁₈, led to the formation of a high‐valent iron–oxo species when the mutant proteins were reacted with H₂O₂. These data demonstrate that these residues in the second coordination sphere tightly control the evolution and the cleavage of the O? O bond of the ferric iron hydroperoxide intermediate that is formed in the SOR active site.     

Iron(III) Located in the Dinuclear Metallo‐β‐Lactamase IMP‐1 by Pseudocontact Shifts

Heterodinuclear metalloenzymes are an important class of metalloproteins, but determining the location of the different metal ions can be difficult. Herein we present a new NMR spectroscopy method that uses pseudocontact shifts (PCS) to achieve this without assumptions about the coordinating ligands. The approach is illustrated with the dinuclear [FeZn] complex of IMP‐1, which is a prototypical metallo‐β‐lactamase (MβL) that confers resistance to β‐lactam antibiotics. Results from single‐crystal X‐ray diffraction were compromised by degradation during crystallization. With [GaZn]‐IMP‐1 as diamagnetic reference, the PCSs unambiguously identified the iron binding site in fresh samples of [FeZn]‐IMP‐1, even though the two metal centers are less than 3.8 Å apart and the iron is high‐spin Fe³⁺, which produces only small PCSs. [FeZn]‐MβLs may be important drug targets, as [FeZn]‐IMP‐1 is enzymatically active and readily produced in the presence of small amounts of Fe³⁺.     

Porous Protein Crystals as Catalytic Vessels for Organometallic Complexes

Porous protein crystals, which are protein assemblies in the solid state, have been engineered to form catalytic vessels by the incorporation of organometallic complexes. Ruthenium complexes in cross‐linked porous hen egg white lysozyme (HEWL) crystals catalyzed the enantioselective hydrogen‐transfer reduction of acetophenone derivatives. The crystals accelerated the catalytic reaction and gave different enantiomers based on the crystal form (tetragonal or orthorhombic). This method represents a new approach for the construction of bioinorganic catalysts from protein crystals.     

The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison

In the classic novella "The Strange Case of Dr. Jekyll and Mr. Hyde", Robert Louis Stevenson paints a stark picture of the duality of good and evil within a single man. Botulinum neurotoxin (BoNT), the most potent known toxin, possesses an analogous dichotomous nature: It shows a pronounced morbidity and mortality, but it is used with great effect in much lower doses in a wide range of clinical scenarios. Recently, tremendous strides have been made in the basic understanding of the structure and function of BoNT, which have translated into widespread efforts towards the discovery of biomacromolecules and small molecules that specifically modulate BoNT activity. Particular emphasis has been placed on the identification of inhibitors that can counteract BoNT exposure in the event of a bioterrorist attack. This Review summarizes the current advances in the development of therapeutics, including vaccines, peptides, and small-molecule inhibitors, for the prevention and treatment of botulism.     

Crystal Structure of Dimeric Cu(II) Complex {μ,μ'‐acetato O,O bis [N‐salicylidene‐2‐amino‐pyridine‐methanolato N,N,O]} : perchlorate

The crystal structure of the title complex has been solved using X‐ray diffraction data.The compound crystallizes from aqueous ethanol solvent in the triclinic system, space group P‐1, with unit cell parameters: a = 8.9532(1), b = 12.7423(3), c = 14.9012(3) Å, α = 73.767(1), β = 75.322(1), γ = 77.496(1)°, Z = 2, V = 1559.4(5) ų. The trial structure was determined by automated Patterson methods and subsequent difference Fourier techniques using DIRDIF98 and refined to a final R‐factor of 0.064. The copper ion Cu1 adopts a (4+1) square‐pyramidal geometry defined by the tridentate N‐salicylidimine dianions and the neutral monodentate pyridine ligand in the basal plane. The apical position is occupied by a solvent methanol molecule at a distance of 2.341(4) Å. The copper Cu2 adopts a square‐planar geometry.